W. Li

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Mark E. Robson, Nadine Tung, Pierfranco Conté et al. · Annals of Oncology · 2019 · 725 citations · Full text

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

F. Wang, Xiaoli Wei, Fenggong Wang et al. · Annals of Oncology · 2019 · 466 citations · Full text

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

Yue Shi, Mei Dong, Xiaoting Hong et al. · Annals of Oncology · 2015 · 384 citations

Lymphoid Neoplasia, Medicine, Immunology +7

First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study

Yuankai Shi, L. Wang, Baohui Han et al. · Annals of Oncology · 2017 · 333 citations

Advanced Lung Disease, Medicine, Pathology +9

Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial

Ye Guo, Myung‐Ju Ahn, Anthony T.�C. Chan et al. · Annals of Oncology · 2019 · 57 citations · Full text